{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:11:21Z","timestamp":1788495081373,"version":"build-2803163510"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.lungcan.2026.108936","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T16:19:23Z","timestamp":1768925963000},"page":"108936","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Osimertinib dose-reduction and survival in 1L EGFR-mutated metastatic non-small cell lung cancer (mNSCLC)"],"prefix":"10.1016","volume":"213","author":[{"given":"Adam","family":"Barsouk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alec","family":"Heidlauf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keshav","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Rushkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Anran Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Elghawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kurian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Reed-Guy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lova","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charu","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger B.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey","family":"Langer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melina E.","family":"Marmarelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.lungcan.2026.108936_b0005","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med."},{"issue":"9","key":"10.1016\/j.lungcan.2026.108936_b0010","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1200\/JCO.2017.74.7576","article-title":"Osimertinib As First-Line Treatment of EGFR Mutation-positive Advanced Non-Small-Cell Lung Cancer","volume":"36","author":"Ramalingam","year":"2018","journal-title":"J Clin Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2026.108936_b0015","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1200\/JCO.19.00457","article-title":"Osimertinib in patients with Epidermal Growth factor Receptor Mutation-positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: the BLOOM Study","volume":"38","author":"Yang","year":"2020","journal-title":"J Clin Oncol."},{"issue":"18","key":"10.1016\/j.lungcan.2026.108936_b0020","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer","volume":"372","author":"J\u00e4nne","year":"2015","journal-title":"N Engl J Med."},{"issue":"11","key":"10.1016\/j.lungcan.2026.108936_b0025","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.annonc.2020.08.2100","article-title":"Osimertinib versus platinum\u2013pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis","volume":"31","author":"Papadimitrakopoulou","year":"2020","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.lungcan.2026.108936_b0030","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s11523-017-0519-0","article-title":"Osimertinib: a Review in T790M-positive Advanced Non-Small Cell Lung Cancer","volume":"12","author":"Lamb","year":"2017","journal-title":"Targ Oncol"},{"issue":"3","key":"10.1016\/j.lungcan.2026.108936_b0035","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.cllc.2021.01.010","article-title":"Combining Osimertinib with Chemotherapy in EGFR-Mutant NSCLC at Progression","volume":"22","author":"White","year":"2021","journal-title":"Clin Lung Cancer."},{"issue":"17","key":"10.1016\/j.lungcan.2026.108936_b0040","doi-asserted-by":"crossref","first-page":"17731","DOI":"10.1002\/cam4.6393","article-title":"Osimertinib early dose reduction as a risk to brain metastasis control in EGFR-mutant non-small cell lung cancer","volume":"12","author":"Tozuka","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.lungcan.2026.108936_b0045","doi-asserted-by":"crossref","unstructured":"Awano N, Yoh K, Usui K, et al. Outcome of osimertinib-treated patients with epidermal growth factor receptor mutation-positive nonsmall cell lung cancer requiring dose reduction: a secondary analysis of the Reiwa study. Jpn J Clin Oncol. Published online December 13, 2024:hyae173. doi:10.1093\/jjco\/hyae173.","DOI":"10.1093\/jjco\/hyae173"},{"issue":"3","key":"10.1016\/j.lungcan.2026.108936_b0050","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10637-024-01432-4","article-title":"Effect of early dose reduction of osimertinib on efficacy in the first-line treatment for EGFR-mutated non-small cell lung cancer","volume":"42","author":"Hori","year":"2024","journal-title":"Invest New Drugs."},{"issue":"6","key":"10.1016\/j.lungcan.2026.108936_b0055","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/cpt.1956","article-title":"Relationship between Progression-Free Survival, Objective Response Rate, and overall Survival in Clinical Trials of PD-1\/PD-L1 Immune Checkpoint Blockade: a Meta-Analysis","volume":"108","author":"Ye","year":"2020","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.lungcan.2026.108936_b0060","doi-asserted-by":"crossref","unstructured":"Tang, W-C. 581P The associations between afatinib-related adverse events and survival outcomes in patients with lung cancer. Annals of Oncology, Volume 34, S1697.","DOI":"10.1016\/j.annonc.2023.10.659"},{"issue":"7","key":"10.1016\/j.lungcan.2026.108936_b0065","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1001\/jamaoncol.2024.1779","article-title":"Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Non\u2212Small Cell Lung Cancer:A Nonrandomized Controlled Trial","volume":"10","author":"Dong","year":"2024","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.108936_b0070","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1158\/1078-0432.CCR-19-1871","article-title":"Preclinical Comparison of the Blood-brain barrier Permeability of Osimertinib with Other EGFR TKIs","volume":"27","author":"Colclough","year":"2021","journal-title":"Clin Cancer Res."},{"issue":"6","key":"10.1016\/j.lungcan.2026.108936_b0075","article-title":"High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: a Multi-institutional Experience","volume":"3","author":"Piper-Vallillo","year":"2022","journal-title":"JTO Clin Res Rep."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226000310?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226000310?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T18:05:23Z","timestamp":1774029923000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226000310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":15,"alternative-id":["S0169500226000310"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.108936","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Osimertinib dose-reduction and survival in 1L EGFR-mutated metastatic non-small cell lung cancer (mNSCLC)","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.108936","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108936"}}